COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
22/05/2026
Wegovy ® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy ® 7.2 mg in a single-dose pen in the EU in Q3 2026 In the STEP UP trial, Wegovy ® 7.2 mg [...]
Guerbet : Evolution de la composition du Conseil d’administration de Guerbet.
22/05/2026
Evolution de la composition du Conseil d’administration de Guerbet ___________________________________________________________________________ Nomination de Monsieur Antoine Fady en qualité d’administrateur indépendant [...]
Vaya Health and Partners Health Management Announce Merger
22/05/2026
Managed care organizations join to bring strength and stability to North Carolina’s public system of behavioral healthcare Asheville/Gastonia, N.C., May 22, 2026 (GLOBE NEWSWIRE) -- Managed care organizations join to [...]
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
22/05/2026
With a mean weight loss of 16.6% 1 , Wegovy ® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recommends Wegovy ® pill [...]
Cuprina Holdings announces 1-for-8 Share Consolidation
22/05/2026
SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, [...]
Regenix Labs Introduces NMN Supplement Designed to Support Cellular Vitality and Healthy Aging
22/05/2026
Educational wellness guide explores NAD+ support, DNA repair support, and long-term cellular wellness routines Regenix Labs: A wellness-focused company committed to ingredient transparency and sustainable healthy aging [...]
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
22/05/2026
PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S., Saudi Arabia, United [...]
SafeSpace Global Announces New Senior Living Client; Clearview Healthcare Management, Expanding Deployment Across Seven Tennessee Facilities
22/05/2026
Knoxville, TN., May 22, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation ("SafeSpace" or the "Company") (OTCID: SSGC), a leader in multimodal AI-powered, safety and security solutions, dedicated to safety [...]
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
22/05/2026
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing [...]
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
22/05/2026
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC) [...]
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
22/05/2026
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
22/05/2026
Strengthening balance sheet on path to Nasdaq uplisting POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, [...]
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
22/05/2026
Base shelf prospectus is accessible on SEDAR+ NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp [...]
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
22/05/2026
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair [...]
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
22/05/2026
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
22/05/2026
Regulatory milestone expands access to wearable, patient-centric drug delivery for rare disease treatment across Europe CINCINNATI, May 22, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare [...]
Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options
22/05/2026
For decades, supplement research has not supported cartilage regeneration. A randomized, placebo-controlled study in Pharmaceutical Research documented measurable cartilage regeneration biomarkers at 90 days, a [...]
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
22/05/2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic [...]
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
22/05/2026
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Calif., May 22, 2026 [...]

Pages